Skip to content
HowShorted

Ampio Pharmaceuticals Inc. short interest in 2021

In 2021, Ampio Pharmaceuticals Inc.'s disclosed short interest ran from 12.04% of shares outstanding on 15 Jan 2021 to 9.72% on 31 Dec 2021, a change of -2.32 percentage points. The year's high was 13.36% on 30 Jun 2021 and its low 9.72% on 31 Dec 2021, averaging 11.19% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 30.43 days on 15 Oct 2021. Full history: Ampio Pharmaceuticals Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024

Aggregate net short position time series for Ampio Pharmaceuticals Inc. in 2021

2021 in figures

Start of year
12.04% (15 Jan 2021)
End of year
9.72% (31 Dec 2021)
Change
-2.32 pp
High
13.36% (30 Jun 2021)
Low
9.72% (31 Dec 2021)
Average
11.19%
Highest days to cover
30.43 (15 Oct 2021)
SEC filings marked
8

Every report in 2021

Ampio Pharmaceuticals Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 202112.04%6.44
29 Jan 202112.37%4.62
12 Feb 202111.63%5.31
26 Feb 202111.36%6.33
15 Mar 202110.75%8.4910-K filed, results (8-K)
31 Mar 202110.89%10.32
15 Apr 202110.73%17.52
30 Apr 20219.80%11.58
14 May 202110.53%14.0710-Q filed, results (8-K)
28 May 202110.94%17.52
15 Jun 202110.81%10.56
30 Jun 202113.36%6.41
15 Jul 202112.96%21.22
30 Jul 202112.61%21.55
13 Aug 202112.24%13.6810-Q filed, results (8-K)
31 Aug 202111.76%23.86
15 Sep 202111.41%10.35
30 Sep 202111.46%18.30
15 Oct 202110.68%30.43
29 Oct 202110.44%29.30
15 Nov 202110.03%19.4910-Q filed, results (8-K)
30 Nov 202110.01%17.82
15 Dec 202110.10%5.41
31 Dec 20219.72%8.36

See also: Ampio Pharmaceuticals Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.